Mohd. Farooq Shaikh

About

Associate Professor Farooq joined CSU in February 2023 as an Associate Professor in Pharmacy (Pharmacology). He is also appointed as Head of Pharmacy discipline at CSU. He moved from Monash University Malaysia, where he worked for almost 10 years. He is an expert neuropharmacologist, interested in translational neuroscience research. He has published more than 150 international, high-impact articles. He was listed in the Elsevier-Stanford top 2% scientists’ list in 2022. He has won several awards for excellence in research and supervision at Monash University and Malaysian national awards for teaching and research.

Associate Professor Farooq completed his B. Pharm. and M. Pharm. From Rajiv Gandhi University of Health Sciences, Bangalore, India and PhD in Pharmacology from the Institute of Chemical Technology, Mumbai, India, in 2012. He holds adjunct appointments with Monash University Malaysia and Monash University Australia.

Employment

• Charles Sturt University - Orange Campus Associate Professor
  2023 - Present
• Monash University Malaysia Associate Professor
  2021 - 2023
• Monash University Malaysia Senior Lecturer
  2018 - 2021
• Monash University Malaysia Lecturer
  2013 - 2017
• University of Queensland IBRO-APRC Fellow
  2012 - 2012
• Institute of Chemical Technology Research Assistant
  2008 - 2009
• Charles Sturt University

Education

• Institute of Chemical Technology PhD (Pharmacology)
  2008 - 2012
• Rajiv Gandhi University of Health Sciences M. Pharm. (Pharmacology)
  2005 - 2007
• Rajiv Gandhi University of Health Sciences B. Pharm.
  2000 - 2004

Projects & Funding

Projects & funding information is unavailable.

Publications (248)

• Repurposing CNS drugs Zonisamide and Perampanel conjugated with silver nanoparticles as an anti-amoebic agent in combating Granulomatous Amebic Encephalitis (GAE) and Primary Amebic Meningoencephalitis (PAM) infection caused by Acanthamoeba castellanii a…
  Parasite Epidemiology and Control 2026 DOI: 10.1016/j.parepi.2026.e00494
  +Save
• Exploring the antiamoebic potential of zonisamide and perampanel against Naegleria fowleri
  ACS Omega 2026 DOI: 10.1021/acsomega.5c05724
  +Save
• Novel Approaches to Epilepsy Management and Therapeutic Advances
  Neurological Disorders 2026 DOI: 10.1201/9781003500025-6
  +Save
• Zebrafish larvae
  Biomaterials for advanced drug and therapeutics delivery 2026 DOI: 10.1016/B978-0-443-26657-7.00006-4
  +Save
• Gut microbiota and aging
  The potential of intermittent fasting in age-related diseases and precision antiaging therapeutics 2026 DOI: 10.1016/B978-0-443-30060-8.00016-9
  +Save
• Alzheimer's Disease
  2025 DOI: 10.1201/9781003602477-2
  +Save
• Nanoformulations in epilepsy therapy - a systematic review of emerging strategies in status epilepticus
  DARU Journal of Pharmaceutical Sciences 2025 DOI: 10.1007/s40199-025-00575-w
  +Save
• A qualitative study exploring physician perspectives on a cardiac-based seizure prediction digital service for epilepsy management
  Epilepsy & Behavior 2025 DOI: 10.1016/j.yebeh.2025.110689
  +Save
• Improved cognition and memory via PLGA nanoparticle-mediated delivery of curcumin and piperine in an in vivo Alzheimer's disease model
  Drug delivery and translational research 2025 DOI: 10.1007/s13346-025-01945-2
  +Save
• Cardiometabolic outcomes among adults with abdominal obesity and normal body mass index
  JAMA Network Open 2025 DOI: 10.1001/jamanetworkopen.2025.37942
  +Save